Arritmia cardíaca: fibrilação atrial

Autores

  • Otávio Ayres da Silva Neto FCMS/PUC-SP

Palavras-chave:

arritmias cardíacas, fibrilação atrial, tromboembolismo

Resumo

A fibrilação atrial é a alteração supraventricular do ritmo cardíaco mais comum e com uma incidência elevada progressivamente relacionada às idades mais avançadas. Existe um remodelamento atrial com mudanças estruturais (alargamento e fibrose intersticial), que promovem a desorganização rítmica. O tratamento farmacológico ou invasivo por cateteres visa a prevenção das complicações tromboembólicas e a evolução para taquicardiomiopatia numa tentativa de melhorar a qualidade de vida e reduzir a morbimortalidade.

Downloads

Não há dados estatísticos.

Biografia do Autor

Otávio Ayres da Silva Neto, FCMS/PUC-SP

Professor do Depto. de Medicina FCMS/PUC-SP

Referências

Rubart M, Zipes DP. Arrrythmias, sudden death, and syncope. In: Bonow MD, Mann DL, Zipes DP, Libby P, editors. Braunwald's heart disease: a textbook of cardiovascular medicine. 9th edn. New York: Elsevier; 2012.

Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2012 update: a report from the American Heart Association. Circulation. 2012; 124:e2-e220.

Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation. 2004; 110:1042-6.

Gami AS, Hodge DO, Herges RM, Olson EJ, Nykodym J, Kara T, et al. Obstructive sleep apnea, obesity, and the risk of incidentatrial fibrillation. J Am Coll Cardiol. 2007; 49:565-71.

Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the ACC/AHA Task Force and the ESC Committee for Practice Guidelines. J Am Coll Cardiol. 2006; 48:854-906.

Wakili R, Voigt N, Kaab S, Dobrev D, Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest. 2011; 121(8):2955-68.

Schotten U, Verheule S, Kirchhof P, Goatee A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011; 91(1):265-325.

Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol. 2008; 1(1):62-73.

Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res. 2006; 118:321-33.

Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, et al. Selecting patients with atrial fibrillation for anticoagulation: Stroke risk stratification in patients taking aspirin. Circulation. 2004; 110:2287-92.

Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009; 119:1363-9.

Nieuwlaat R, Dinh T, Olsson SB, Camm AJ, Capucci A, Tieleman RG, et al. Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? Eur Heart J. 2008; 29:915.

Akar JG, Jeske W, Wilber DJ. Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction. J Am Coll Cardiol. 2008; 51:1790.

Van Walraven C, Hart RG, Wells GA, Petersen P, Koudstaal PJ, Gullov AL, et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med. 2003; 163:936-43.

Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009; 151:297-305.

Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, et al; ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009; 360:2066-78.

Oden A, Fahlen M, Hart RG. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res. 2006; 117:493-9.

Rose AJ, Ozonoff A, Henault LE, Hylek EM. Warfarin for atrial fibrillation in community-based practice. J Thromb Haemost. 2008; 6:1647-54.

Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007; 370:493-503.

Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, et al; International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009; 360:753-64.

Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007; 116:2563-70.

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-51.

Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: The Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation. 2004; 109:997-1003.

Knight BP, Gersh BJ, Carlson MD, Friedman PA, McNamara RL, Strickberger SA, et al. Role of permanent pacing to prevent atrial fibrillation: Science advisory from the American Heart Association Council on Clinical Cardiology (Subcommittee on Electrocardiography and Arrhythmias) and the Quality of Care and Outcomes Research Interdisciplinary Working Group, in collaboration with the Heart Rhythm Society. Circulation. 2005; 111:240-3.

Blanc JJ, De Roy L, Mansourati J, Poezevara Y, Marcon JL, Schoels W, et al. Atrial pacing for prevention of atrial fibrillation: assessment of simultaneously implemented algorithms. Europace. 2004; 6:371.

Morady F. Catheter ablation of supraventricular arrhythmias: state of the art. J Cardiovasc Electrophysiol. 2004; 15:124-39.

Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2007; 4:816-861. Erratum in: Heart Rhythm. 2009; 6(1):148.

Noheria A, Kumar A, Wylie JV Jr, Josephson ME. Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review. Arch Intern Med. 2008; 168:581-6.

Jais P, Cauchemez B, Macle L, Daoud E, Khairy P, Subbiah R, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation. 2008; 118:2498-505. Erratum in: Circulation. 2009; 120(10):e83.

Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation. 2005; 111:1100-5. Spragg DD, Dalal D, Cheema A, Scherr D, Chilukuri K, Cheng A, et al. Complications of catheter ablation for atrial fibrillation: incidence and predictors. J Cardiovasc Electrophysiol. 2008; 19:627.

Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, et al. Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol. 2009; 53:1798-803.

Prasad SM, Maniar HS, Camillo CJ, Schuessler RB, Boineau JP, Sundt TM 3rd, et al. The Cox maze III procedure for atrial fibrillation: Long-term efficacy in patients undergoing lone versus concomitant procedures. J Thorac Cardiovasc Surg. 2003; 126:1822-8.

Ballaux PK, Geuzebroek GS, van Hemel NM, Kelder JC, Dossche KM, Ernst JM, et al. Freedom from atrial arrhythmias after classic maze III surgery: A 10-year experience. J Thorac Cardiovasc Surg. 2006; 132:1433-40.

Gillinov AM, Sirak J, Blackstone EH, McCarthy PM, Rajeswaran J, Pettersson G, et al. The Cox maze procedure in mitral valve disease: predictors of recurrent atrial fibrillation. J Thorac Cardiovasc Surg. 2005; 130:1653-60.

Gaynor SL, Schuessler RB, Bailey MS, Ishii Y, Boineau JP, Gleva MJ, et al. Surgical treatment of atrial fibrillation: predictors of late recurrence. J Thorac Cardiovasc Surg. 2005; 129:104.

Khargi K, Hutten BA, Lemke B, Deneke T. Surgical treatment of atrial fibrillation: a systematic review. Eur J Cardiothorac Surg. 2005; 27:258-65.

Schneeberger EW, Osterday RM. Lateral placement of bipolar clamp facilitates pulmonary vein isolation. Ann Thorac Surg. 2007; 84:1412-3.

Downloads

Publicado

2012-09-28

Como Citar

1.
Silva Neto OA da. Arritmia cardíaca: fibrilação atrial. Rev. Fac. Ciênc. Méd. Sorocaba [Internet]. 28º de setembro de 2012 [citado 21º de dezembro de 2024];14(3):87-94. Disponível em: https://revistas.pucsp.br/index.php/RFCMS/article/view/9678

Edição

v. 14 n. 3 (2012)

Seção

Revisão

Licença

Os autores no momento da submissão transferem os direitos autorais, assim, os manuscritos publicados passam a ser propriedade da revista.

O conteúdo do periódico está licenciado sob uma Licença Creative Commons 4.0, esta licença permite o livre acesso imediato ao trabalho e que qualquer usuário leia, baixe, copie, distribua, imprima, pesquise ou vincule aos textos completos dos artigos, rastreando-os para indexação, passá-los como dados para o software, ou usá-los para qualquer outra finalidade legal.